Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03708328
Title	A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Hoffmann-La Roche
Indications	Advanced Solid Tumor lung small cell carcinoma melanoma esophagus squamous cell carcinoma lung non-small cell carcinoma esophageal adenosquamous carcinoma
Therapies	RO7121661
Age Groups:	adult \| senior
Covered Countries	USA \| NZL \| FRA \| ESP